文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

优化全脑放疗剂量分割:前瞻性3期试验结果

Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-10-22

该事后分析基于NCCTG N107C随机试验中92例术后接受全脑放疗的脑转移患者,比较30 Gy/10次与37.5 Gy/15次两种分割方案。结果显示延长疗程未显著改善认知失败时间、手术床控制、颅内肿瘤控制或总生存,但≥3级不良事件风险显著增加。

要点

  • 延长全脑放疗疗程未显著改善认知失败时间、肿瘤控制或总生存。
  • 37.5 Gy/15次组≥3级不良事件风险显著高于30 Gy/10次组(54% vs 31%)。
  • 对于推荐全脑放疗的脑转移患者,短程大分割方案仍是当前标准治疗。

核心结论

  • 延长全脑放疗疗程未降低认知缺陷风险、未改善乏氧手术腔的肿瘤控制或治疗指数,且不良事件显著增加。
  • 对于推荐全脑放疗的脑转移患者,短程大分割方案仍是当前标准治疗。

研究设计与样本

  • NCCTG N107C [Alliance]/CEC.3随机试验的事后分析,纳入194例脑转移患者,其中92例术后接受全脑放疗。
  • 各中心预先确定全脑放疗剂量分割方案(30 Gy/10次或37.5 Gy/15次),采用Kaplan-Meier估计、log rank检验和Fisher精确检验进行分析。

主要发现

  • 92例中49例(53%)接受30 Gy/10次,43例(47%)接受37.5 Gy/15次,93%患者完成全脑放疗。

关键数值与推荐

  • 全脑放疗剂量分割方案为30 Gy/10次或37.5 Gy/15次,由各中心预先确定。
  • 延长疗程(37.5 Gy/15次)与短程(30 Gy/10次)相比,认知失败时间、手术床控制、颅内肿瘤控制和总生存均无显著差异。

临床怎么用

  • 对于脑转移术后需全脑放疗的患者,优先选择短程大分割方案(如30 Gy/10次)而非延长疗程。
  • 延长全脑放疗疗程未显示认知保护或肿瘤控制获益,且不良事件增加,应避免常规使用。

局限性

  • 本研究为事后分析,样本量有限(92例),剂量分割方案由中心预先确定而非个体随机。
  • 基线原发肿瘤类型在两组间分布不均衡(肺癌组织学比例差异有统计学意义)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Whole brain radiation therapy (WBRT) remains a commonly used cancer treatment, although controversy exists regarding the optimal dose/fractionation to optimize intracranial tumor control and minimize resultant cognitive deficits. METHODS AND MATERIALS: NCCTG N107C [Alliance]/CEC.3 randomized 194 patients with brain metastases to either stereotactic radiosurgery alone or WBRT after surgical resection. Among the 92 patients receiving WBRT, sites predetermined the dose/fractionation that would be used for all patients treated at that site (either 30 Gy in 10 fractions or 37.5 Gy in 15 fractions). Analyses were performed using Kaplan-Meier estimates, log rank tests, and Fisher's exact tests. RESULTS: Among 92 patients treated with surgical resection and adjuvant WBRT, 49 were treated with 30 Gy in 10 fractions (53%), and 43 were treated with 37.5 Gy in 15 fractions (47%). Baseline characteristics, including cognitive testing, were well balanced between groups with the exception of primary tumor type (lung cancer histology was more frequent with protracted WBRT: 72% vs 45%, P = .01), and 93% of patients completed the full course of WBRT. A more protracted WBRT dose regimen (37.5 Gy in 15 fractions) did not significantly affect time to cognitive failure (hazard ratio [HR], 0.9; 95% confidence interval [CI], 0.6-1.39; P = .66), surgical bed control (HR, 0.52 [95% CI, 0.22-1.25], P = .14), intracranial tumor control (HR, 0.56 [95% CI, 0.28-1.12], P = .09), or overall survival (HR, 0.72 [95% CI, 0.45-1.16], P = .18). Although there was no reported radionecrosis, there is a statistically significant increase in the risk of at least 1 grade ≥3 adverse event with 37.5 Gy in 15 fractions versus 30 Gy in 10 fractions (54% vs 31%, respectively, P = .03). CONCLUSIONS: This post hoc analysis does not demonstrate that protracted WBRT courses reduce the risk of cognitive deficit, improve tumor control in the hypoxic surgical cavity, or otherwise improve the therapeutic ratio. Adverse events were significantly higher with the lengthened course of WBRT. For patients with brain metastases where WBRT is recommended, shorter course hypofractionated regimens remain the current standard of care.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Trifiletti DM, Ballman KV, Brown PD, et al. Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3). Int J Radiat Oncol Biol Phys. 2019. PMID: 31654784. doi:10.1016/j.ijrobp.2019.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。